Abstract Dendritic cells (DCs) are central orchestrators of antitumor immunity, yet their therapeutic potential is constrained by dysfunction and inadequate activation within solid tumors. Here we report chimeric antigen receptor-engineered DCs (CAR-DCs) that prime T cells and reprogram the tumor microenvironment.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Congyi
Contact Congyi, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack